Occam Places Chief Legal Officer at Public Obesity Biotech, Metsera
Metsera (Nasdaq: MTSR) is a clinical-stage biotech focused on developing the next generation of medicines for obesity and metabolic disease. In May 2025, Occam placed Matt Lang as its Chief Legal Officer & Corporate Secretary.
Prior to Metsera, Matt had a multidimensional business career culminating in his service as Chief Business & Legal Officer of the public, clinical-stage cell therapy biotech, Lyell Immunopharma. He came to Lyell from Myovant, where he strategically built the legal and administrative functions of the company and guided the organization through its $2.9B acquisition by Sumitomo Pharma.
A classics major as an undergrad, Matt also received his JD from the University of Pennsylvania.
Related Placements
Occam Global is a trusted executive search, consulting, and investment partner for leaders and investors shaping the future of life sciences, deep tech, and venture capital. Since 2012, we’ve helped build high-performing teams and advised visionary companies from stealth to public markets. Our success stems from exceptional access to rare talent, deep sector expertise, and a commitment to results guided by elevated ethics and enlightened aggression.